Study To Characterize Mass Balance, Absolute Bioavailability, Fraction Absorbed And Pharmacokinetics Of 14C PF-06882961

Phase 1

Completed

• Conditions: Healthy Volunteer
• Interventions: Drug: [14C]PF-06882961, 50 mg; Drug: PF-06882961, 50 mg and [14C]PF-06882961, 100 ug

• Registration Number: NCT04495140
• Lead Sponsor: Pfizer

Brief Summary

This study is a Phase 1, open-label, non-randomized, 2-period, fixed sequence study to characterize the metabolic profile and routes of excretion of oral \[14C\]PF-06882961 and to evaluate the absolute oral bioavailability of PF-06882961 and fraction absorbed of \[14C\]PF-06882961 in reference to intravenous \[14C\]PF-06882961 in healthy male participants.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-07-16
• Study Start: 2020-07-22
• Study First Submitted QC: 2020-07-29
• Study First Posted: 2020-07-31
• Primary Completion: 2020-10-15
• Study Completion: 2020-10-15
• Status Verified: 2020-11
• Last Update Submitted: 2020-11-23
• Last Update Posted: 2020-11-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 6

Inclusion Criteria

• Male participants between 18 to 54 years of age
• Healthy and capable of signing informed consent document
• Willing to comply to all scheduled visits, lab tests, lifestyle considerations and study procedures
• Body mass index (BMI) of 17.5 to 30 kg/m2; and a total body weight ≥50 kg (110 lb).

Read More

Exclusion Criteria

• acute or chronic medical or psychiatric condition including recent (within the past year)
• Surgical procedures like gastrectomy, cholecystectomy, Irregularity in bowel movements
• Use of prescription or non-prescription drugs and dietary and herbal supplements within 14 days prior to the first dose of investigational product.
• Previous administration with an investigational drug within 60 days (or as determined by the local requirement) preceding the first dose of investigational product used in this study.
• Known prior participation in a trial involving PF-06882961 or known intolerance to a GLP-1R agonist.
• A positive urine drug test on screening or Day -1.
• Screening supine blood pressure (BP) ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), following at least 5 minutes of supine rest. If BP is ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), the BP should be repeated 2 more times and the average of the 3 BP values should be used to determine the participant's eligibility.
• Participants with abnormalities in clinical laboratory tests including ECGs, vital signs, liver function tests, myocardial infarction
• Positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibody (HCVAb). Hepatitis B vaccination is allowed.
• History of alcohol or tobacco abuse or binge drinking and/or any other illicit drug use or dependence within past 6 months.
• Subjects whose occupation requires exposure to radiation or monitoring of radiation exposure.
• Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing.
• History of sensitivity to heparin or heparin-induced thrombocytopenia only if heparin is planned to flush intravenous catheters.
• Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or Pfizer employees, including their family members, directly involved in the conduct of the study.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Oral [14C]PF-06882961, 50 mg	[14C]PF-06882961, 50 mg	In this arm, a single oral dose of \[14C\]PF-06882961, 50 mg will be administered as a liquid formulation.
Oral PF-06882961 50 mg and intravenous [14C]PF-06882961 100 ug	PF-06882961, 50 mg and [14C]PF-06882961, 100 ug	In this arm, single oral dose of unlabeled PF-06882961, 50 mg will be administered as a liquid formulation. Approximately 3 hours after the administration of the unlabeled oral dose, a single dose of \[14C\]PF-06882961, 100 ug, will be administered via intravenous infusion.

Primary Outcome Measures

Name	Time	Method
Total recovery of radioactivity in urine and feces, following oral administration of [14C] PF-06882961 in period 1	Baseline through approximately hour 312 (day 14). Period 1 is 14 days	Total recovery of radioactivity in urine and feces, and both routes combined, expressed as a percent of total oral radioactive dose administered.

Secondary Outcome Measures

Name	Time	Method
Metabolite profiling/identification in plasma, urine, and feces	0, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96-312 hour (hr)	Metabolic profiling/identification and determination of relative abundance of \[14C\]PF-06882961 and the metabolites of \[14C\]PF-06882961 in plasma, urine, and feces.
Plasma AUClast to describe PK of total radioactivity following administration of single, oral dose of [14C] PF-06882961	0, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 hr	Area under the plasma radioactivity-time profile from time 0 to time of the last quantifiable concentration (Clast)
Plasma Cmax to describe the plasma PK of PF-06882961 following administration of single, oral dose of [14C] PF-06882961	0, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 hr	Maximum Observed Plasma Concentration
Plasma AUClast to describe PK of PF-06882961 following administration of single, oral dose of [14C] PF-06882961	0, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 hr	Area under the plasma concentration-time profile from time 0 to time of the last quantifiable concentration (Clast)
Plasma AUCinf to describe plasma PK of PF-06882961 following administration of single, oral dose of [14C] PF-06882961	0, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 hr	AUCinf is Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).
Mean residence Time (MRT )following administration of a single, intravenous dose of [14C]PF 06882961	0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72 hr	where MRT is the Mean Residence Time
Systemic Clearance (CL) following administration of a single, intravenous dose of [14C]PF 06882961	0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72 hr	Systemic clearance, CL is a quantitative measure of the rate at which a drug substance is removed from the body.
Plasma Cmax to describe plasma PK of total radioactivity following administration of single, oral dose of [14C] PF-06882961	0, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 hr	Maximum Observed Plasma Radioactivity
Plasma Tmax to describe the PK of total radioactivity following administration of single, oral dose of [14C]PF-06882961	0, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 hr	Time to Reach Maximum Observed Plasma Radioactivity
Plasma AUCinf to describe plasma PK of total radioactivity following administration of single, oral dose of [14C] PF-06882961	0, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 hr	AUCinf is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).
Plasma elimination t½ to describe plasma PK of total radioactivity following administration of single, oral dose of [14C] PF-06882961	00, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 hr	Plasma elimination half-life is the time measured for the plasma radioactivity to decrease by one half.
Plasma Tmax to describe the plasma PK of PF-06882961 following administration of single, oral dose of [14C]PF-06882961	0, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 hr	Time to Reach Maximum Observed Plasma Concentration
Number of participants with ECG measurements above/below certain threshold	baseline, day 5-14 of period 1 (period 1 is 14 days), day 3-8 of period 2 (period 2 is 8 days)	ECGs
Number of participants with vital measurements above/below certain threshold	baseline, day 5-14 of period 1 (period 1 is 14 days), day 3-8 of period 2 (period 2 is 8 days)	vitals
Volume of distribution at steady state (Vss) following administration of a single, intravenous dose of [14C]PF 06882961	0, 1, 2, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72 hr	Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.
Absolute oral bioavailability (F)	0, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 hr	Absolute oral bioavailability following administration of a single oral dose of PF-06882961 in reference to a single intravenous dose of \[14C\]PF-06882961
Fraction of dose absorbed following single oral administration of [14C]PF-06882961	0, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96-312hr	Fraction absorbed calculated from ratio of total urinary radioactivity following oral administration in reference to intravenous administration
Number of participants with adverse events	Baseline in Period 1 up to 32 days after the period 2 doses, for a total of approximately 46 days	adverse events
Plasma elimination t½ to describe plasma PK of PF-06882961 following administration of single, oral dose of [14C] PF-06882961	00, 0.5, 1, 2, 3, 4, 6, 9, 12, 16, 24, 36, 48, 72, 96 hr	Plasma elimination half-life is the time measured for the plasma radioactivity to decrease by one half.
Number of participants with safety laboratory test results above/below certain threshold	baseline, day 5-14 of period 1 (period 1 is 14 days), day 3-8 of period 2 (period 2 is 8 days)	lab tests

Trial Locations

Locations (2)

PRA Health Sciences; 🇳🇱 Groningen, Netherlands

PRA Health Sciences Utrecht; 🇳🇱 Utrecht, Netherlands